{'fraction_non_alphanumeric': 0.02433281004709576, 'fraction_numerical': 0.007849293563579277, 'mean_word_length': 6.162921348314606, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Adhesion molecule expression and response to chemotactic agents of human monocyte‐derived macrophages

Human monocyte‐derived macrophages have been proposed as agents of anti‐tumour immunotherapy. The aim of the present study was to investigate in vitro the properties of these cells likely to control their recruitment to the sites of inflammation and tumours. The expression of adhesion molecules involved in the binding of monocytes to endothelial cells was modified during monocyte‐macrophage differentiation, with a significant increase in CD11c, CD14 and intercellular adhesion molecule‐1 (ICAM‐1). Monocyte‐derived macrophages were sensitive to chemoattractants, in particular to the monocyte‐specific chemokine monocyte chemotactic protein‐1 (MCP‐1). They responded by an increased expression of adhesion molecules and were attracted by the cytokine in an under‐agarose migration assay. The migration response, however, decreased after days 4–5 of monocyte differentiation into macrophage. In conclusion, human monocyte‐derived macrophages show alterations of surface structures involved in the recognition of inflammatory endothelium. This may explain why the cells are poorly recruited to the sites of inflammation and tumours when introduced into the circulation.